In order for ZnPP to be effective, it must be present early during reperfusion since systemic administration of ZnPP reduces stroke size and brain edema formation at 24hrs when the ZnPP is given before or immeeiately upon reperfusion after 2hr of focal ischemia, but not if it is given 2hrs into the reperfusion period. 54 In the same study, we were unable to reduce brain injury with ZnPP in permanent focal ischemia. 54 Although the need for preischemic or early-postischemic administration of the ZnPP is consistent with the early appearance of IL-1 in ischemic brain, it remains uncertain whether or not ZnPP's mechanism of action is through blockade of IL-1 receptors since ZnPP has other actions. The ability of ZnPP to inhibit heme oxygenase is particu larly troublesome in this regard because heme oxygenase, an enzyme that produces carbon monoxide, has been shown to be induced in brain during ischemia. 55, 56 A more specific approach to blocking the actions of IL-1 is made possible by the identification of an endo genous peptide which acts as a competitive antagonist at the IL-1 receptor. It has been named IL-lra because no agonist activity has been identified. 11, 13, 57, 58 IL-lra is usually produced by the same cells as IL-1 in the normal brain and the peptide is structurally similar to IL-1. 13, 59, 60 In situ hybridization detects IL-1ra mRNA in various brain regions such as hippocampus, paraventricular nu cleus (PVN) of the hypothalamus, choroid plexus, and cerebellum. 61 IL-1ra can inhibit many actions of IL-1 in vivo and in vitro62 although it appears to have a greater affinity for the IL-1RI receptor. 16
Relton and Rothwell63 were the first to show that intraventricular injection of recombinant human IL-lra 30min before and 10min after permanent occlusion of the middle cerebral artery in rats results in a 50% decrease in stroke size at 24hr. This protection could not be explained by a change in the body temperature of the animals. Similarly, frequent systemic administration of IL-1ra improves the neurological scores and reduces the loss of body weight, the size of the stroke, the number of leukocytes, and the appearance of necrotic neurons over a 7 day period after the induction of permanent focal ischemia in rats. 60 Systemic IL-1ra administration is also effective in reducing stroke size and the neuronal loss that occurs following exposure to hypoxia-ischemia in immature rats. 64
As an alternative to the repeated intraventricular injection or the frequent systemic administration of high doses of IL-1ra, we used an adenoviral vector to induce the overexpression of human IL-1ra in rat brain65 and more recently in mouse brain (unpublished results). Intraventricular injection of recombinant, replication deficient adenoviruses carrying the Rous sarcoma virus promoter and either the human IL-1ra cDNA (Ad. RSVIL-1ra) or a reporter gene (Ad. RSVlacZ), results in expression of the transgenes primarily in the ependymal cells that line the ventricular system. As early as 1 day following transfection, Il-ira is detectable in the CSF and brain tissue and maximum levels are achieved after 5-7 days. When the middle cerebral artery is permanently occluded in these rats, the animals that received the Ad.RSVIL-lra have a 64% reduction in stroke size at 24 hr compared to animals that received Ad.RSVIacZ and a 77% reduction compared to animals that received intraventricular saline.65 Brain edema at 24 hr is also reduced in rats that received Ad. RS VIL-1ra as compared to Ad.RSVIacZ (Fig 1) . In mice, stroke size is reduced by about 50% compared to either Ad.RSVIacZ or saline injected controls (unpublished results). Neither the rate of cerebral blood flow during ischemia65 nor the body temperature (unpublished results with mice) is affected by the IL-lra overexpression. These studies demonstrate that the presence of elevated levels of IL lra in the extracellular fluid of the brain greatly attenuates the brain damage that occurs during 24 hr of permanent focal ischemia and they indicate that IL-1 plays a role in ischemic brain injury.
Since IL-ira blocks the actions of both IL-la and IL-1(3, the studies described above do not indicate which of these cytokines is responsible for ischemic brain injury. This has been addressed using specific antibodies against IL-1(3 or by using mice that are unable to synthesize IL 1(3. Yamasaki et a150 injected neutralizing antibodies to mouse IL-1(3 into the cerebral ventricles of rats immedi ately after 60 min of focal ischemia. Brain edema, stroke size, and neutrophil infiltration were significantly reduced 24 hr later. We are currently studying "knockout" mice with an abnormal ICE, the enzyme that converts pro-IL 1(3 to IL-1(3.66 The cerebral blood flow rate is equally reduced by permanent middle cerebral artery occlusion in ICE knockouts as compared to the SV129 strain that served as the source of the embryonic stem cells from which the ICE knockouts were derived. However, stroke size is 73% smaller in the ICE knockouts as compared to SV129 strain (Fig 2) . This reduction in stroke size is similar to that achieved with overexpression of IL-1ra in mice.
Mechanisms of Action of Interleukin-13 in Cerebral Ischemia
The studies described above provide compelling evi dence that IL-i1 is produced in brain during ischemia and that it contributes in some way to producing brain injury. Although the studies conducted to date have not identified the mechanisms by which IL-1(3 injures brain during ischemia, the models that have been developed should allow such studies to move forward. There are several known actions of IL-1 in brain that will initially receive the most attention (Fig 3) . Brain temperature markedly influences neurological outcome after ischemia, particularly in temporary ischemia. 67-69 Since one of the most prominent actions of IL-1 in the brain is the induction of fever, 24, 70 this may 
